DANAHERDD

DANAHER

195.32EURD
−2.28−1.15%
At close at Mar 7, 16:45 GMT
EUR
No trades
See on Supercharts

4DHR fundamentals

Key facts

Market capitalization‪140.55 B‬EUR
Founded1984
Employees (FY)‪63 K‬
CEORainer M. Blair
About

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Ownership
‪‪714.71 M‬‬
Free Float shares
‪‪685.65 M‬‬ (95.93%)
Closely held shares
‪‪29.06 M‬‬ (4.07%)
Free Float shares
‪‪685.65 M‬‬ (95.93%)
Closely held shares
‪‪29.06 M‬‬ (4.07%)
Capital structure
Market cap
‪‪140.55 B‬‬
Debt
‪‪16.56 B‬‬
Minority interest
‪‪6.76 M‬‬
Cash & equivalents
‪‪2.01 B‬‬
Enterprise value
‪‪155.11 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪140.55 B‬‬
Price to earning ratio (P/E)
40.30x
Price to sales ratio (P/S)
6.50x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
40.30x
Price to sales ratio (P/S)
6.50x
Valuation ratios
‪0.00‬
‪2.20‬
‪4.40‬
‪6.60‬
‪8.80‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪15.00‬
‪30.00‬
‪45.00‬
‪60.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪10.0%‬
‪12.5%‬
‪15.0%‬
‪17.5%‬
‪20.0%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪1.60 B‬‬
‪‪3.20 B‬‬
‪‪4.80 B‬‬
‪‪6.40 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪1.60 B‬‬
‪‪3.20 B‬‬
‪‪4.80 B‬‬
‪‪6.40 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪1.60 B‬‬
‪‪3.20 B‬‬
‪‪4.80 B‬‬
‪‪6.40 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Diagnostics
Life Sciences
Biotechnology
By country
Period: 2024
United States
Western Europe
High-growth Markets
China
Other Developed Markets
North America

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪1.60 B‬‬
‪‪3.20 B‬‬
‪‪4.80 B‬‬
‪‪6.40 B‬‬
Actual
Estimate
Earnings
Next:Apr 17, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪0.60‬
‪1.20‬
‪1.80‬
‪2.40‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
20.42%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
0.51%
Next payment
0.297
Next ex-date
Mar 28, 2025
Dividend history
‪0.25%‬
‪0.31%‬
‪0.37%‬
‪0.43%‬
‪0.49%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.30‬
‪0.60‬
‪0.90‬
‪1.20‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪5.00 B‬‬
‪‪10.00 B‬‬
‪‪15.00 B‬‬
‪‪20.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪17.00 B‬‬
‪‪34.00 B‬‬
‪‪51.00 B‬‬
‪‪68.00 B‬‬
Assets
Liabilities